Finally, in the case of patients with locally advanced ESCC who cannot undergo surgery after neoadjuvant treatment, the phase III SKYSCRAPER-07 (NCT04543617) is comparing tiragolumab (anti- T cell immunoreceptor with Ig and ITIM domains (TIGIT) agent) plus atezolizumab (anti-PD-L1 agent) versus atezolizumab versus placebo as maintenance treatment in patients who have not progressed after chemoradiotherapy [9]. Here, CD274 is linked to esophageal squamous cell carcinoma.